Opus Genetics (IRD) EPS (Basic) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.81% |
| Dec 31, 2025 | 43.57% |
| Sep 30, 2025 | 5.40% |
| Jun 30, 2025 | 22.53% |
| Mar 31, 2025 | 22.71% |
| Dec 31, 2024 | -23.06% |
| Sep 30, 2024 | 9.96% |
| Jun 30, 2024 | 13.23% |
| Mar 31, 2024 | 14.10% |
| Dec 31, 2023 | -18.47% |
| Sep 30, 2023 | 16.31% |
| Jun 30, 2023 | 30.21% |
| Mar 31, 2023 | 18.73% |
| Dec 31, 2022 | 74.83% |
| Sep 30, 2022 | -40.63% |
| Jun 30, 2022 | -52.51% |
| Mar 31, 2022 | 17.40% |
| Dec 31, 2021 | -55.18% |
| Sep 30, 2021 | -13.97% |
| Jun 30, 2021 | -45.41% |
| Mar 31, 2021 | -77.96% |
| Dec 31, 2020 | -183.61% |
| Sep 30, 2020 | -75.18% |
| Jun 30, 2020 | -84.71% |
| Mar 31, 2020 | -112.67% |
| Dec 31, 2019 | -114.11% |
| Sep 30, 2019 | -117.79% |
| Jun 30, 2019 | -114.93% |
| Mar 31, 2019 | -47.11% |
| Dec 31, 2018 | -55.18% |
| Sep 30, 2018 | -151.69% |
| Jun 30, 2018 | -117.19% |
| Mar 31, 2018 | -139.62% |
| Dec 31, 2017 | -115.90% |
| Sep 30, 2017 | -5.92% |
| Jun 30, 2017 | 43.10% |
| Mar 31, 2017 | -114.59% |
| Dec 31, 2016 | -31.95% |
| Sep 30, 2016 | -45.41% |
| Jun 30, 2016 | -5.92% |
| Mar 31, 2016 | -31.95% |
| Dec 31, 2015 | 7.79% |
| Sep 30, 2015 | -55.29% |
| Jun 30, 2015 | 16.74% |